Analysis of Correlation Between Serum Oncostatin-M and Disease Severity and Mortality in Hospitalized Patients with Community-Acquired Pneumonia

Abstract

Purpose

The aim of this study was to investigate the level of serum tumor suppressor factor (Oncostatin-M, OSM) in patients with community-acquired pneumonia (CAP) and evaluate its predictive value for the severity and prognosis of pneumonia, so as to improve the ability to identify the risk of death in CAP patients.

Patients and Methods

A total of 110 patients with CAP admitted to the hospital from November 2020 to November 2021 were enrolled in this prospective study. Clinical data of all patients were collected. According to the 2016 edition of “Guidelines for the Diagnosis and Treatment of Community-acquired Pneumonia in Chinese Adults”, the patients were divided into non-severe CAP (NSCAP)(n=55) and severe CAP (SCAP)(n=55). At the same time, they were divided into a survival group (n=96) and a death group (n=14) by tracking the survival of patients in the hospital. The OSM concentration of CAP patients on the first day after admission was determined by enzyme-linked immunosorbent assay. All clinical data were statistically and graphed using SPSS V23.0 and Grahpad Prim 8.

Results

Compared with NSCAP, patients with SCAP had higher serum OSM concentration on the day of admission, which was negatively correlated with LYM and positively correlated with WBC, NEU, CRP, IL-6, IL-8, IL-10, CURB-65 score, and PSI score. The level of OSM in the dead patient group was significantly higher than that in the surviving patient group. OSM and PSI scores were independent risk factors for in-hospital mortality in CAP patients. Kaplan-Meier survival curve showed that OSM≥76pg/mL was more advantageous in predicting mortality in patients with CAP.

Conclusion

The level of the OSM is closely related to the severity and prognosis of CAP and may be a new biomarker for the prognosis of CAP patients.

Keywords:

• community-acquired pneumonia
• severity of disease
• oncostatin-M
• mortality

Data Sharing Statement

The datasets generated and analyzed during the current study are not publicly available due to health privacy concerns but are available from the corresponding author on reasonable request.

Ethics Approval and Consent to Participate

The protocol of this study was approved by the Ethics Committee of the Qingdao Municipal Hospital (Approval No. 2020CXJJ001-052). This study was in compliance with the Declaration of Helsinki and informed consent was obtained from all patients or their families before this study.

Acknowledgments

The authors thank all the patients who participated in this study.

Author Contributions

Peikun-Teng, Xiudi Han and Xuedong-Liu contributed to the conception of the study. Peikun-Teng drafted the manuscript under the help of Xiudi-Han and Xuedong-Liu. Xingyu-Zhang and Hong-Wang took part in drafting, revising, conducting statistical analysis or critically reviewing the article. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

Additional information

Funding

This study was funded by the Qingdao Municipal Hospital Clinical Diagnosis and Treatment Technology Innovation Fund (CXJJ-034).